Status:
COMPLETED
Rivaroxaban in Patients With Atrial Fibrillation Undergoing PCI
Lead Sponsor:
IHF GmbH - Institut für Herzinfarktforschung
Collaborating Sponsors:
Bayer
Conditions:
Non-valvular Atrial Fibrillation
Acute Coronary Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
This study evaluates the antithrombotic therapy in patients suffering from atrial fibrillation after stent implantation in Germany. Patients prescribed with the novel oral anticoagulant Rivaroxaban wi...
Detailed Description
Patients suffering from non-valvular atrial fibrillation and presenting with an acute coronary syndrome require special attention with regard to antithrombotic therapy. Current guidelines recommend us...
Eligibility Criteria
Inclusion
- Age ≥18 years and capable of giving written informed consent
- Known or newly diagnosed non-valvular atrial fibrillation
- PCI with stent implantation during index hospital stay
- Written informed consent for participation in observational study (incl. telephone follow-up)
- Not simultaneously participating in any randomized trial
Exclusion
- None
Key Trial Info
Start Date :
January 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 24 2021
Estimated Enrollment :
1632 Patients enrolled
Trial Details
Trial ID
NCT03315650
Start Date
January 1 2018
End Date
June 24 2021
Last Update
March 31 2022
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Kerckhoff-Klinik
Bad Nauheim, Germany, 61231
2
Segeberger Kliniken
Bad Segeberg, Germany, 23795
3
Gesundheitszentrum Bitterfeld-Wolfen
Bitterfeld-Wolfen, Germany, 06749
4
Klinikum Links der Weser
Bremen, Germany, 28277